This company has the same predicament as BIQ - it has revenue,...

This company has the same predicament as BIQ - it has revenue, products/services validated to a large degree but its losses has widened. Staff costs way too high - if they cant bring it down, more pain ahead.

I bought 9SP in early Dec at 9.6c on Equity Story's recommendation and I think a few of you may have also followed their tip. But the price action since then was just straight down, as if some insiders were wanting out. Got out shortly at $1.8k loss, if I had not, it would have been $10k loss by now. Told Equity Story they have to do stop loss (they are not doing that for all their loss trades including BUD)- it was a sell a long while ago - you can buy back now or a bit lower.

Somewhat strange that 9SP and BIQ have mcap of about $15m with annual revenues circa $6-7m while other companies with barely any revenues like YOJ, BUD and BRN are commanding mcap > $100m! You would think that the companies with reasonable revenues should be better stead, right? Or perhaps the market may be thinking that if they have revenues but still have large losses, when can they be profitable, whereas for the other non-revenue generating businesses, they are still having the faith that they can land large revenues and profits would ensue.

You may be glad that I have changed the sentiment to HOLD from SELL but where this heads going forwards rest much on management action to reduce operating cost.